GMP cell manufacturing for new clinical cell therapies is a rapidly expanding need in the life science space. This presentation will discuss the foundation of cell therapy product development considerations when preparing to launch into manufacture of materials in support of early Phase clinical trials to commercialization. Historical development of an autologous canine mesenchymal stem-cell product that facilitated the ability to rapidly respond to develop and manufacture an allogeneic human MSC product for treatment of COVID-19 patients with ARDS will be presented.
- MSC isolation from tissue to success in primary cell culture
- Characterization of cell lines
- Avoiding development pitfalls in the scale-up of cell therapy manufacturing
Carolyn Wrightson, Ph.D.
Chief of Operations
Austin Mogen, Ph.D.
Senior Field Application Scientist
Corning Incorporated | Life Science
The Corning Scientific Seminar Series is a series of free, online technical presentations that provide novel tips, best practices and proven techniques to help advance your research. Delivered by scientists to scientists, these one-hour broadcasts offer useful information and tips for lab technicians and researchers.…